Study adds clinical evidence for lipid emulsion in pet neurotoxicosis

Intravenous lipid emulsion therapy may do more than clinicians have been able to prove so far in suspected companion animal neurotoxicosis. In a 34-case series spanning eight veterinary hospitals, researchers found that, by the end of infusion, xenobiotics were more concentrated in the lipid fraction than the aqueous fraction in 28 of 34 dogs and cats, suggesting in vivo “sequestration” is happening in many cases. Early neurologic improvement within 4 to 6 hours was seen in 14 of 34 animals and was associated with higher lipid-to-aqueous xenobiotic ratios, while the commonly used lipophilicity marker log P did not predict partitioning or short-term outcome. The work was posted as a preprint on February 25, 2026, by investigators affiliated with Utrecht University and collaborators, and it builds on a literature base that has relied heavily on case reports and retrospective series. (research-portal.uu.nl)

Why it matters: For veterinary professionals, the study adds a useful piece of mechanistic evidence to an area where ILE is already used off-label, but where hard prospective data have been thin. The findings support the idea that ILE can shift some toxicants into the plasma lipid phase in real patients, yet they also reinforce that response is inconsistent and not easily predicted from log P alone. That matters for case selection, client communication, and expectations at triage: ILE may help some neurotoxic cases, but it’s still adjunctive therapy, not a guaranteed antidote. Clinicians also need to weigh known risks, including reported pulmonary, metabolic, and other adverse effects described in prior veterinary literature. (research-portal.uu.nl)

What to watch: Watch for peer-reviewed publication, larger controlled studies, and any practical guidance on which toxicants or clinical presentations are most likely to benefit from ILE. (research-portal.uu.nl)